You are here:  > Authors

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Please note that the journal is running later than expected due to COVID-19.

During the transition, you can still access content to which you have subscribed via the AVT website. Content will be available to access via the SAGE Journals platform in Summer 2021. https://uk.sagepub.com/en-gb/eur/antiviraltherapy.

If you have any questions relating to the transfer, please contact journaltransitions@sagepub.com

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Subscriptions Please note that Antiviral Therapy is running later than expected due to COVID-19.

All subscription queries should be sent to subscriptions@sagepub.co.uk

Orders via subscription agents
If you are using a subscription agent, please instruct your agent as usual. We are notifying all subscription agents of this change of publisher and they will be able to handle your query.

Pricing enquiries 2021 Antiviral Therapy pricing set by International Medical Press will be honoured.

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Please continue to submit your manuscripts to the AVT ScholarOne site (https://mc.manuscriptcentral.com/avt)

For papers already in peer-review, you will be informed of a decision as soon as possible. All accepted papers not assigned to a 2020 issue will now be published by SAGE.

Authors

Antiviral Chemistry & Chemotherapy publishes original research that focuses on strategic issues in the field, from basic science through study design and safety monitoring, to the results of clinical trials in all phases.

Why submit to Antiviral Chemistry & Chemotherapy?

Antiviral Chemistry & Chemotherapy is a well-respected, peer-reviewed journal that concerned with the biochemistry, mode of action, chemistry, pharmacology and virology of antiviral compounds 
Antiviral Chemistry & Chemotherapy is an official journal of the International Society of Antiviral Research
♦ Our international Editorial Board includes leaders in all major research areas, ensuring high-quality standards for our publication
♦ We gurantee a first decision within 7 weeks of submission on average
♦ Accepted articles can be referenced with a DOI and timely publication is enabled by early publication on this website.

This section of our website includes helpful information to guide new authors through the process of preparing a manuscript for submission as well as to provide valuable information for returning authors. Please read our Editorial Policy and Author Guidelines before submitting your manuscript.

If you have any further questions regarding our publishing process, author guidelines, submission or support, please contact our Editorial Office.

Copyright © 2022 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.